--- title: "16:10 ETRegencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit" type: "News" locale: "en" url: "https://longbridge.com/en/news/286813948.md" description: "Glancy Prongay Wolke & Rotter LLP announces that investors who lost money in Regencell Bioscience Holdings Limited (NASDAQ: RGC) have the opportunity to lead a securities fraud class action lawsuit. The lawsuit alleges that from October 28, 2024, to October 31, 2025, the company failed to disclose vulnerabilities to market manipulation, exposing investors to significant financial risks. Interested parties must act before June 23, 2026, to participate." datetime: "2026-05-18T20:10:39.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286813948.md) - [en](https://longbridge.com/en/news/286813948.md) - [zh-HK](https://longbridge.com/zh-HK/news/286813948.md) --- # 16:10 ETRegencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit , /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ: RGC). **IF YOU SUFFERED A LOSS ON YOUR REGENCELL INVESTMENTS, CLICK** **HERE** **BEFORE JUNE 23, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT** **What Is The Lawsuit About?** The complaint filed alleges that, between October 28, 2024 and October 31, 2025, Defendants failed to disclose to investors that: (1) Regencell was vulnerable and/or subject to market manipulation; (2) the resulting volatility in the market for the Company's ordinary shares exposed Regencell's investors to significant financial risk; (3) all the foregoing subjected Regencell to a heightened risk of regulatory and/or governmental scrutiny and enforcement action, as well as significant legal, monetary, and reputational harm; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. **Contact Us To Participate or Learn More: **If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq., Glancy Prongay Wolke & Rotter LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: \[email protected\] Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at www.glancylaw.com. Follow us for updates on LinkedIn, Twitter, or Facebook. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. **Contact Us: **Glancy Prongay Wolke & Rotter LLP, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 **Charles Linehan **Email: \[email protected\] Telephone: 310-201-9150 Toll-Free: 888-773-9224 Visit our website at: www.glancylaw.com. SOURCE Glancy Prongay Wolke & Rotter LLP ### Related Stocks - [RGC.US](https://longbridge.com/en/quote/RGC.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) ## Related News & Research - [Skye Bioscience opens higher-dose Cohort 2 in nimacimab obesity Phase 2a study](https://longbridge.com/en/news/287053007.md) - [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md) - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md) - [Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention](https://longbridge.com/en/news/286884841.md) - [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)